ecancermedicalscience

Case Report

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure

21 Oct 2019
Guilherme Harada, Fernando Costa Santini, Felipe Sales Nogueira Amorim Canedo, Leandro Jonata de Carvalho Oliveira, Henrique Bortot Zuppani, Gilberto de Castro Jr

Osimertinib is a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. Pneumonitis is a severe adverse event (AE) related to osimertinib treatment which appears to be more frequent when associated with concurrent or previous anti-PD(L)1 exposure. Data regarding the efficacy and safety of osimertinib rechallenge, especially in the setting of central nervous system (CNS) metastases, are scarce. We herein describe a case of a 53-year-old patient with metastatic EGFR-mutated NSCLC, who developed pneumonitis after osimertinib treatment and was successfully rechallenged with 40 mg daily osimertinib, with CNS response. This dose reduction strategy may be an option for selected patients with brain metastases after tyrosine kinase inhibitors-induced AEs.

Article metrics: 765 views
602
163

Related Articles

Muhammad Shahid Iqbal, Joseph Carlow, Fiona McDonald, Philip Atherton, Helen Turnbull, Sandeep Singhal, Timothy Simmons, Paula Mulvenna, Josef Kovarik, Rhona McMenemin, Jill Gardiner, Alastair Greystoke
Viviane Teixeira Loiola de Alencar, Maria Nirvana Formiga, Vladmir Cláudio Cordeiro de Lima
Valentina Pinzi, Valeria Landoni, Federica Catani, Roberta Lazzari, Barbara Alicja Jereczek-Fossa, Roberto Orecchia